{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-012891","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2025-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.429170+00:00","generated_at":"2026-05-26T23:01:25.126004+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"CERo Therapeutics regains Nasdaq minimum bid price compliance, moves to Capital Market","bullets":["Received Nasdaq confirmation of compliance with Bid Price Requirement on Feb 12, 2025.","Common stock transferred to Nasdaq Capital Market per Nasdaq Panel's extension conditions.","Extension granted until April 22, 2025; company working toward remaining conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-012891","json":"https://secwatch.observer/filing/0001213900-25-012891.json","markdown":"https://secwatch.observer/filing/0001213900-25-012891.md","text":"https://secwatch.observer/filing/0001213900-25-012891.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025012891/0001213900-25-012891-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390025012891/ea0230890-8k_cerotherap.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:01:25.126004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}